Use of leptin antagonists for the treatment of diabetes
AssigneeSmithKline Beecham Corporation
InventorsMichael Cawthorne, Valur Emilsson, Yong-Ling Liu
Life of this patent
Estimating the term…
Abstract
The use of an antagonist of leptin for the manufacture of a medicament for the treatment of disorders resulting from deficiencies in insulin secretion, hyperglycaemia and insulin resistance.
Claims9
The use of an antagonist of leptin for the manufacture of a medicament for the treatment of disorders resulting from deficiencies in insulin secretion and of hyperglycaemia.
3 The use of an antagonist of leptin for the manufacture of a medicament for the treatment of insulin resistance.
A use according to claim 3, for the treatment of insulin resistance associated with obesity.
A method for the treatment of disorders resulting from deficiencies in insulin secretion and of hyperglycaemia, in a human or non-human mammal, which method comprises the administration to human or non-human mammal in need of such treatment, an effective, pharmaceutically acceptable, non-toxic amount of an antagonist of leptin.
A method for the treatment of insulin resistance, which method comprises the administration to human or non-human mammal in need of such treatment, an effective, pharmaceutically acceptable, non-toxic amount of an antagonist of leptin.
A pharmaceutical composition for the treatment of disorders resulting from deficiencies in insulin secretion and of hyperglycaemia, comprising an antagonist of leptin, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
A pharmaceutical composition for the treatment of insulin resistance, comprising an antagonist of leptin, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.